Reliance Global Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 23, 2021, reporting events occurring on December 21 and 22, 2021. Reliance Global Group, Inc. (RELI), a Florida corporation, announced a strategic expansion into the Medicare supplement and health insurance sector alongside a significant capital raise to fund the transaction.
Key Financial Metrics and Transaction Details
The filing details two primary financial events: an asset acquisition and a private placement financing.
- Asset Purchase Agreement: The Company agreed to purchase the Medicare supplement and related health insurance business of Healthcare Insurance Company, LLC.
- Revised Purchase Price: Following an amendment on December 22, 2021, the total consideration is $20,096,250, comprised of $18,138,750 in cash and 1,957,500 shares of common stock valued at approximately $1.50 per share (based on the 180-day average).
- Private Placement Proceeds: The Company entered into a securities purchase agreement to raise approximately $20,000,000.
- Securities Issued: The offering includes 2,670,892 common shares, 9,076 Series B convertible preferred shares (stated value $1,000 each), and Series B warrants to purchase up to 9,779,952 common shares.
- Pricing: The purchase price for common shares and warrants is $4.09 per share. Preferred shares are convertible at $4.09 per share.
- Financing Contingency: The asset purchase closing is contingent on the Company securing financing sufficient to cover the cash portion of the purchase price plus working capital.
Material Changes and Transaction Structure
The filing represents a material change in the Company's capital structure and business operations.
- Amendment to Acquisition: The original agreement (Dec 21) was amended (Dec 22) to increase the cash portion of the purchase price from $16,638,750 to $18,138,750 and reduce the equity portion to 1,957,500 shares.
- Lock-up Provisions: Half of the shares issued for the acquisition are locked until December 21, 2022, with the remainder locked until December 21, 2023.
- Warrant Terms: Series B Warrants issued in the private placement have a 200% warrant coverage ratio relative to the underlying shares and preferred conversion shares. They feature a "full ratchet" anti-dilution provision with a floor price of $3.84 per share until shareholder approval is obtained.
- Placement Agent Fees: EF Hutton was engaged as the placement agent, receiving an 8.0% cash fee, a 2.0% expense fee, reimbursement of up to $70,000, and warrants to purchase 244,499 shares (5% of the total issuance).
Outlook, Risks, and Contingencies
Management's ability to execute the strategic pivot depends on the successful closing of the private placement.
- Closing Conditions: The asset purchase is contingent on the Company's ability to close financing proceeds sufficient to pay the cash purchase price and working capital requirements. The private placement itself is subject to customary closing conditions.
- Dilution Risk: The issuance of significant equity and warrants with full ratchet protection creates potential dilution for existing shareholders, particularly if future issuances occur below the $4.09 exercise price.
- Regulatory Status: The securities issued in the private placement are unregistered and subject to restrictive legends. The Company is relying on Section 4(a)(2) and Rule 506 exemptions.
- Shareholder Approval: The warrant floor price of $3.84 applies until the Company receives shareholder approval for the sale of securities in the private placement.
Investor Verification Checklist
- Verify the successful closing of the $20 million private placement to confirm the asset acquisition can proceed.
- Review the definitive Asset Purchase Agreement (Exhibit 10.5) for specific representations, warranties, and indemnification terms regarding the acquired Medicare business.
- Assess the impact of the "full ratchet" anti-dilution provision on future capital raising and existing shareholder value.
- Confirm the timeline for shareholder approval required to lift the $3.84 floor price on the warrants.
- Monitor the lock-up expiration dates (Dec 2022 and Dec 2023) for the 1,957,500 shares issued to the seller.